In addition, since LSD1 regulates p85 gene expression, the combined treatment of PI3K inhibitors which target PI3K enzymatic activity and LSD1 inhibitors may achieve synergistic effect in treating PCa patients and such treatments need to be further tested in the pre-clinical animal models of CRPC. This evidence concerns the gene KDM1A and posterior cortical atrophy.